



**Recommendation to the Cancer Systemic Therapy Policy Committee (CSTPC)  
from Capital District Health Authority/Cancer Care Nova Scotia**

**Guidelines for the Role of Dasatinib in Chronic Myelogenous Leukemia (CML) and  
Philadelphia Chromosome Acute Lymphoblastic Leukemia (Ph $\oplus$  ALL)**

**Approved Use:**

**Dasatinib:** As a **single agent** for the treatment of adults with chronic, accelerated or blast phase CML and Ph $\oplus$  ALL with resistance or intolerance to prior therapy including imatinib. These criteria include:

1. Patients with CML in chronic phase who are intolerant of imatinib.
  2. Patients with CML in chronic phase who are resistant (imatinib 600mg/day).
  3. Patients with CML that have progressed to accelerated phase or blast phase crisis while on therapy including imatinib.
  4. Patients with resistant or intolerant Ph $\oplus$  ALL.
- This policy recommendation represents a **new guideline document** and a restriction of dasatinib for the treatment of adult patients with chronic, accelerated or blast phase CML and Ph $\oplus$  ALL with resistance or intolerance to prior therapy including imatinib.